Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS
Isao Tawara(Mie University), Hiroshi Shiku(Research Institute of Fundamental and Clinical Immunology), Naoki Inoue(Mukogawa Women's University), Sachiko Okamoto(Takara (Japan)), Makoto Murata(Nagoya University), Ikuei Nukaya(Biota Pharmaceuticals (United States)), Seitaro Terakura(Nagoya University Hospital), Daisuke Tomura(Biota Pharmaceuticals (United States)), Tetsuya Nishida(Nagoya University), Yoko Inaguma(Fujita Health University), Shinichi Kageyama, Naoyuki Katayama(The University of Tokyo), Yoshihiro Miyahara(Center for Personalized Cancer Treatment), Kazushi Tanimoto(Ehime University), Masahiro Masuya(Mie University), Yoshiki Akatsuka(Nagoya University), Hideto Chono(Takara (Japan)), Hiroshi Fujiwara(National Heart Lung and Blood Institute), Masaki Yasukawa(Ehime Prefectural University of Health Science), Nobuhiko Emi(Fujita Health University), Tomohide Kidokoro(Tokyo University of Science), Hiroaki Ikeda(Nagasaki University), Tomoki Naoe(National Hospital Organization), Junichi Mineno(Takara (Japan))
Cited by 169
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
|Blood|2008|957